99TcmO-4甲状腺显像联合Tg/TSH对分化型甲状腺癌术后残甲的评估价值

刘学，韦智晓，李俊红，周世亮，李蔼峰，彭盛梅，张筱楠，田甜

(1广西医科大学第一附属医院，南宁530000；2怀化市第一人民医院)

99TcmO-4甲状腺显像联合Tg/TSH对分化型甲状腺癌术后残甲的评估价值

刘学1，2，韦智晓1，李俊红1，周世亮2，李蔼峰1，彭盛梅1，张筱楠1，田甜1

(1广西医科大学第一附属医院，南宁530000；2怀化市第一人民医院)

甲状腺肿瘤，分化型；甲状腺核素扫描；甲状腺球蛋白；促甲状腺激素

1 资料与方法

1.1 临床资料 选择2014年1月～2015年11月广西医科大学第一附属医院收治的DTC患者302例，男84例、女218例，年龄18～79(40.65±13.73)岁。均行甲状腺全切或次全切除术，经病理检查证实为甲状腺乳头状癌或滤泡状癌；均首次接受清甲治疗，且符合清甲治疗标准[1，2]。排除有远处转移或甲状腺球蛋白抗体(TgAb)阳性者。术后3～4周均接受131I清甲治疗，单次131I为2 960～4 810 MBq口服，住院观察5～7 d。

1.2 血清TSH、Tg、TgAb检测 患者甲状腺显像前1 d早晨空腹采集肘正中静脉血3 mL，3 000 r/min离心3～5 min，提取血清，密闭保存于-20 ℃冰箱中备用。采用化学发光法(美国贝克曼DXI 800型全自动化学发光仪)检测血清TSH、Tg、TgAb。试剂盒由贝克曼公司提供。

2 结果

3 讨论

[1] 中华医学会核医学分会.131I治疗分化型甲状腺癌指南(2014版)[J]. 中华核医学与分子影像杂志, 2014, 34(4):265-278.

[2] Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016,26(1):1-133.

[3] Tsai CJ, Cheng CY, Shen HY, et al. Tc-99m imaging in thyroidectomized differentiated thyroid cancer patients immediately before I-131 treatment[J]. Nucl Med Commun, 2016,37(2):182-187.

[4] Rosario PW, Xavier AC, Calsolari MR. Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and131I activity in patients with thyroid cancer and low risk of recurrence[J]. Thyroid, 2011,21(1):49-53.

[5] Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer[J]. N Engl J Med, 2012, 366(18):1663-1673.

[6] Teoh CM, Rohaizak M, Chan KY, et al. Pre-ablative diagnostic whole-body scan following total thyroidectomy for well-differentiated thyroid cancer: is it necessary[J]. Asian J Surg, 2005,28(28):90-96.

[7] Jeon EJ, Jung ED. Diagnostic whole-body scan may not be necessary for intermediate-risk patients with differentiated thyroid cancer after low-dose (30 mCi) radioactive iodide ablation[J]. Endocrinol Metab, 2014,29(1):33-39.

[8] Silberstein EB. Comparison of outcomes after123I versus131I preablation imaging before radioiodine ablation in differentiated thyroid carcinoma[J]. J Nucl Med, 2007,48(7):1043-1046.

[9] Aydin F, Sipahi M, Budak ES, et al. Role of Tc-99m pertechnetate for remnant scintigraphy, post-thyroidectomy, and serum thyroglobulin and antithyroglobulin antibody levels in the patients with differentiated thyroid cancer[J]. Ann Nucl Med, 2015,29(10):1-8.

[10] Kueh SS, Roach PJ, Schembri GP. Role of Tc-99m pertechnetate for remnant scintigraphy post-thyroidectomy[J]. Clin Nucl Med, 2010,35(9):671-674.

[11] 谭天秩.临床核医学[M].北京:人民卫生出版社,2013:370-376.

[12] Giovanella L, Suriano S, Ricci R, et al. Postsurgical thyroid remnant estimation by99mTc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma[J]. Head neck, 2011,33(4):552-556.

[13] Nadig MR, Pant GS, Chandrashekhar B. Usefulness of99mTc-pertechnetate single-photon emission computed tomography in remnant mass estimation of postsurgical patients of differentiated thyroid cancer during internal dosimetry[J]. Nucl Med Commun, 2008,29(9):809-814.

[14] 张英杰,林岩松,梁军.甲状腺癌失分化机制的研究进展[J].中华核医学与分子影像杂志,2014,34(4):327-330.

广西壮族自治区科学技术厅科技攻关与新产品试制项目(桂科攻0861003);广西壮族自治区科学技术厅基础性研究项目(桂科基0779027)。

韦智晓(E-mail:weizhixiao196493@126.com)

10.3969/j.issn.1002-266X.2017.05.022

R736.1

B

1002-266X(2017)05-0067-03

2016-09-05)